Does Cigna Cover Trulicity? Coverage Rules, Prior Auth, and Appeals Explained

What Cigna's Formulary Actually Says About Trulicity

Cigna places Trulicity on Tier 3 or Tier 4 of most commercial formularies, meaning it is a covered drug but carries a higher cost-share than generic metformin or older sulfonylureas. The exact tier depends on whether your plan uses Cigna's Open Access Plus, LocalPlus, or a self-funded employer formulary negotiated separately. Tier 3 specialty cost-shares commonly run $75, $150 per fill before deductible; Tier 4 can reach $150, $300 [1].

Cigna's pharmacy-benefit drug lists are updated quarterly. Employers who self-fund their health plan may carve out GLP-1 receptor agonists entirely or place them under a separate specialty-pharmacy benefit managed by Express Scripts, which Cigna acquired in 2018. Always verify your specific plan's formulary at MyCigna.com or call the member services number on your insurance card before assuming the commercial formulary applies to you.

The FDA approved dulaglutide (Trulicity) in September 2014 for glycemic control in adults with type 2 diabetes, with a supplemental approval in 2020 adding cardiovascular risk reduction in patients with established cardiovascular disease or multiple risk factors [2]. Cigna's coverage policies mirror those FDA-approved indications. A prescription written for obesity or body weight alone, without a documented type 2 diabetes diagnosis (ICD-10: E11.x), will almost certainly generate an automatic denial before a human reviewer even reads the chart [3].

Prior Authorization Criteria: What Cigna Requires

Prior authorization for Trulicity on Cigna is rated moderate difficulty, meaning approval is routine when documentation is complete but denial is common when records are incomplete. Cigna's standard PA criteria for GLP-1 receptor agonists in type 2 diabetes typically require all of the following [4]:

1. A confirmed type 2 diabetes diagnosis with HbA1c documented in the past 12 months.
2. Evidence that metformin was trialed and either failed to achieve target HbA1c or was contraindicated/not tolerated. Cigna generally accepts an HbA1c above 7.0% despite at least 90 days of metformin at the maximally tolerated dose as sufficient failure documentation.
3. Prescriber attestation that the patient received diabetes self-management education or a referral to it.
4. In some regional plans, documentation that a DPP-4 inhibitor (sitagliptin, etc.) or SGLT-2 inhibitor (empagliflozin, dapagliflozin) was also trialed if the patient has no contraindication to those agents.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as preferred add-on therapy when atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease is present, regardless of HbA1c [5]. If your patient carries any of those comorbidities, explicitly cite the ADA guideline language in the PA submission. Cigna's medical directors recognize that guideline citation and it reduces the likelihood of a step-therapy denial.

The HealthRX PA Documentation Checklist for Trulicity / Cigna

Clinicians submitting a Trulicity PA to Cigna should include, in a single fax packet:

• Most recent HbA1c lab result (date and value)
• Metformin trial dates, doses, and reason for transition (inadequate control, GI intolerance, renal contraindication)
• Any cardiovascular, renal, or heart-failure comorbidities with ICD-10 codes
• Current full medication list showing all diabetes agents trialed
• Cigna's specific PA request form (form number varies by region; request it from Cigna provider services at 1-800-88CIGNA)
• A brief clinical narrative of 3, 5 sentences summarizing the treatment rationale

Incomplete packets are the single most common cause of initial PA denial. Sending everything in one fax reduces back-and-forth by an average of 6, 10 business days based on published insurer PA timeline data [6].

Step Therapy: Do You Have to Try Another Drug First?

Step therapy is Cigna's practice of requiring a patient to try one or more lower-cost drugs before the insurer will pay for Trulicity. On many Cigna commercial plans, the required step for a GLP-1 receptor agonist is metformin plus at least one of the following: a sulfonylurea (glipizide, glimepiride), an SGLT-2 inhibitor, or a DPP-4 inhibitor [7].

Patients who already carry a cardiovascular disease diagnosis may qualify for a step-therapy exemption. The REWIND trial (N=9,901; median follow-up 5.4 years) demonstrated that dulaglutide 1.5 mg weekly reduced the composite of nonfatal MI, nonfatal stroke, and CV death by 12% versus placebo (HR 0.88 to 95% CI 0.79, 0.99, P=0.026) in patients with type 2 diabetes who had either established CVD or multiple CV risk factors [8]. When a prescriber documents this trial's findings alongside an established CVD diagnosis, Cigna's policy often allows bypassing the DPP-4 or SGLT-2 step. Cite the REWIND Lancet publication directly in the PA narrative [8].

Seventeen states have enacted step-therapy reform laws requiring insurers to grant exemptions when a patient's physician determines that the preferred drug is clinically inappropriate. If you practice in California, New York, Texas, Florida, or Illinois, check your state's specific statute, because Cigna must comply with those protections for fully insured plans (though not for self-funded ERISA plans) [9].

What Happens When Cigna Denies Trulicity

Cigna's denial letter will specify one of three reasons: not medically necessary, step therapy not completed, or non-covered benefit. Each reason requires a different appeal strategy.

Level 1 Internal Appeal. File within 180 days of the denial date. Submit a letter of medical necessity signed by the prescribing physician, all documentation from the PA checklist above, and any peer-reviewed citations supporting the clinical decision. Cigna must respond within 30 days for non-urgent cases and 72 hours for urgent/expedited requests under ACA internal appeal timelines [10]. The ACA requires insurers to provide a full and fair review, meaning a reviewer different from the one who issued the initial denial must evaluate the case [10].

Level 2 Internal Appeal. If Level 1 fails, request a peer-to-peer call between the prescribing physician and a Cigna medical director. This call alone resolves a meaningful share of Tier 2 denials. Bring the ADA 2024 Standards of Care language and the REWIND data to the call [8][5].

External Independent Review (IRO). After exhausting internal appeals, any Cigna member in a fully insured plan has the right to an external review by an Independent Review Organization under state and federal law [11]. The IRO decision is binding on Cigna. External review overturn rates for GLP-1 receptor agonist denials are not published nationally, but state insurance department data from California and New York show external reviewers overturn insurer decisions in roughly 39 to 45% of all prescription drug cases [12].

Step-by-step appeal timeline to calendar:

• Day 0: Receive denial letter. Note the denial reason and the appeal deadline.
• Days 1, 5: Gather updated labs, updated medication list, peer-reviewed citations.
• Days 6, 10: Submit Level 1 appeal with complete packet.
• Days 11, 40: Await Cigna's Level 1 decision (30-day clock runs from receipt).
• If denied: Request peer-to-peer call within 10 business days.
• If still denied: File for external IRO review within 4 months of final internal denial (federal deadline) [11].

Does Cigna Cover Trulicity for Weight Loss?

No. Cigna does not cover Trulicity for weight loss or obesity as a standalone indication on any standard commercial plan, because the FDA has not approved dulaglutide for that purpose [2]. Weight-loss coverage applies to drugs with an explicit FDA obesity label: semaglutide 2.4 mg (Wegovy), tirzepatide 2.5 to 15 mg (Zepbound), and orlistat (Xenical/Alli). Even those drugs face separate PA requirements under Cigna's obesity-management benefit, which many employer plans exclude entirely [13].

If a patient has both type 2 diabetes and obesity, the diabetes indication is the correct one to submit. Physicians should not list obesity as the primary diagnosis on a Trulicity PA. Doing so triggers an automatic denial pathway in Cigna's pharmacy benefit management system. Document diabetes as the primary condition and note the metabolic benefit as a secondary clinical rationale only [14].

The ADA and the American Association of Clinical Endocrinology (AACE) 2022 Consensus Statement explicitly support GLP-1 receptor agonist use in patients with type 2 diabetes who are overweight or obese, framing weight management as a benefit of diabetes treatment rather than a separate indication [15]. Quoting that consensus in a PA submission reinforces the diabetes-first framing.

Trulicity Cost With and Without Cigna Coverage

The list price for Trulicity is approximately $931 per month for a box of four single-dose pens (4 weekly injections). Patients paying cash at a retail pharmacy without any discount will pay close to that figure [16].

With Cigna coverage after prior authorization is approved, the actual out-of-pocket cost depends on the plan's tier structure and whether the annual deductible has been met. A typical Tier 3 cost-share of 30% coinsurance on a $931 drug equals about $279 per fill before deductible; after deductible, the same coinsurance applies. Out-of-pocket maximums cap total annual spending, but a $931/month drug can exhaust the OOP maximum within a few months on high-coinsurance plans [17].

Lilly's Trulicity Savings Card reduces cost-share to as low as $0, $25 per month for eligible commercially insured patients, including those on Cigna commercial plans [18]. The card is not valid for patients covered by Medicare, Medicaid, or any federal or state government program. Enrollment is free at Lilly's website; the savings apply at the point of sale at participating pharmacies. Patients on Cigna who have approved PA coverage and who activate the savings card before the first fill often pay under $30/month regardless of their deductible status.

The GoodRx cash price for Trulicity varies by pharmacy but typically ranges from $850 to $930 per month, offering minimal savings versus list price for a brand biologic with no generic equivalent [19]. Dulaglutide has no FDA-approved generic as of January 2025; biosimilar development is ongoing but no product has launched in the United States [20].

Clinical Background: Why Trulicity Gets Prescribed

Dulaglutide is a GLP-1 receptor agonist administered as a once-weekly subcutaneous injection available in four doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. The 0.75 mg dose is the starting dose; the 4.5 mg dose was added in the 2020 supplemental approval after showing additional HbA1c reduction and weight benefit in the AWARD-11 trial (N=1,842) [21].

In AWARD-11, the 4.5 mg dose reduced HbA1c by 1.77 percentage points from baseline versus 1.36 percentage points for the 1.5 mg dose at 36 weeks, and produced 4.7 kg mean weight loss versus 3.0 kg, both differences statistically significant (P<0.001) [21]. This dose-response evidence supports clinical use of titration when initial doses fail to achieve glycemic targets, and it can support a PA that argues against switching to a different agent class.

The REWIND cardiovascular outcomes trial enrolled 9,901 patients with type 2 diabetes, of whom 31.5% had established cardiovascular disease and 68.5% had CV risk factors only. The median HbA1c at baseline was 7.2%, lower than in most other GLP-1 CVOT trials, making REWIND results particularly relevant for earlier-stage patients [8]. The 12% relative risk reduction in major adverse cardiovascular events (MACE) was consistent across prespecified subgroups, including patients without prior CVD [8].

Cigna's medical policy for GLP-1 agents in patients with type 2 diabetes and established ASCVD often uses CVOT data as a basis for bypassing step therapy. Prescribers treating patients with prior MI, stroke, or symptomatic peripheral arterial disease should include the REWIND citation and the patient's relevant history in every PA submission.

Renal dosing is not required for dulaglutide; the drug can be used across all stages of chronic kidney disease, which is an advantage over metformin and some SGLT-2 inhibitors in patients with eGFR <30 [22]. Documenting CKD in the PA reinforces the clinical rationale for choosing dulaglutide over a renally contraindicated alternative.

How Specialty Pharmacies Affect Cigna Coverage

Cigna often routes GLP-1 receptor agonists through its specialty pharmacy network (Accredo, a subsidiary of Express Scripts) rather than allowing dispensing at retail chain pharmacies. Patients who receive a 90-day supply through Accredo may pay a different cost-share than those filling at CVS or Walgreens. Prescribers should check whether Cigna's plan requires specialty dispensing; a prescription sent to a non-contracted specialty pharmacy may be rejected even after PA approval [23].

For patients who receive a mail-order prescription through Accredo, the PA approval is often embedded in the dispensing workflow. The specialty pharmacist at Accredo can also assist with prior-authorization submissions directly, which can reduce administrative burden on the prescribing office. Ask the patient to call Accredo at the number on the Cigna EOB to initiate specialty pharmacy dispensing as soon as the prescription is written [24].

Compounded Dulaglutide: Cigna Does Not Cover It

Some compounding pharmacies have marketed compounded dulaglutide injections at lower prices. Cigna explicitly excludes compounded versions of FDA-approved drugs from formulary coverage in nearly all commercial plan contracts [25]. Beyond the coverage exclusion, the FDA has not determined dulaglutide to be in shortage (unlike semaglutide, which appeared on the FDA shortage list in 2022), so compounded dulaglutide does not fall under the temporary outsourced-compounding permissions that applied to some semaglutide products [26]. Patients considering compounded dulaglutide should be counseled that neither Cigna reimbursement nor FDA safety oversight of that specific compounded product applies.